• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人 4-1BBL 的细胞外结构域增强了树突状细胞诱导的细胞毒性 T 淋巴细胞的功能。

Extracellular domain of human 4-1BBL enhanced the function of cytotoxic T-lymphocyte induced by dendritic cell.

机构信息

Tianjin Third Central Hospital Affiliated to Tianjin Medical University, Tianjin Key Laboratory of Artificial Cells, Tianjin 300170, China.

出版信息

Cell Immunol. 2011;271(1):118-23. doi: 10.1016/j.cellimm.2011.06.013. Epub 2011 Jun 23.

DOI:10.1016/j.cellimm.2011.06.013
PMID:21745658
Abstract

Interaction of costimulatory molecules and their receptors is crucial for tumor lysate-pulsed dendritic cells (sensitized DC, sDC) to promote T cell activation, clonal expansion and its antitumor immunity. To augment the costimulatory signal may regulate the interaction between DC and cytotoxic T lymphocyte (CTL) and consequently enhance the antitumor response. The costimulatory ligand and receptor pair of 4-1BB/4-1BBL is one of the main factors in the costimulation of CTL. We explored the adjuvant role of a recombinant human 4-1BBL extracellular domain (ex4-1BBL) in modulating CTL activation induced by HepG2 antigen-loaded DC (sDC). The augment effects of sDC in combination with ex4-1BBL on the proliferation, activation, cell survival and cytotoxicity against HepG2 cells of CTL were examined. In the presence of ex4-1BBL, sDC exhibited markedly augmented effects on the above four functions of CTL. These results demonstrate that ex4-1BBL plays an important role in the costimulation pathway for DC-mediated CTL's activation, which might be a useful adjuvant factor for DC-based cancer biotherapy.

摘要

共刺激分子及其受体的相互作用对于肿瘤裂解物脉冲树突状细胞(致敏 DC,sDC)促进 T 细胞激活、克隆扩增及其抗肿瘤免疫至关重要。增强共刺激信号可能调节 DC 和细胞毒性 T 淋巴细胞(CTL)之间的相互作用,从而增强抗肿瘤反应。4-1BB/4-1BBL 的共刺激配体和受体对是 CTL 共刺激的主要因素之一。我们探讨了重组人 4-1BBL 细胞外结构域(ex4-1BBL)在调节负载 HepG2 抗原的 DC(sDC)诱导的 CTL 激活中的佐剂作用。检测了 sDC 与 ex4-1BBL 联合对 CTL 的增殖、激活、细胞存活和对 HepG2 细胞的细胞毒性的增强作用。在 ex4-1BBL 的存在下,sDC 对 CTL 的上述四种功能表现出明显的增强作用。这些结果表明,ex4-1BBL 在 DC 介导的 CTL 激活的共刺激途径中发挥重要作用,可能是基于 DC 的癌症生物治疗的有用佐剂因子。

相似文献

1
Extracellular domain of human 4-1BBL enhanced the function of cytotoxic T-lymphocyte induced by dendritic cell.人 4-1BBL 的细胞外结构域增强了树突状细胞诱导的细胞毒性 T 淋巴细胞的功能。
Cell Immunol. 2011;271(1):118-23. doi: 10.1016/j.cellimm.2011.06.013. Epub 2011 Jun 23.
2
Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting.白血病树突状细胞诱导的白血病特异性T细胞反应性通过靶向4-1BB得以增强。
Clin Cancer Res. 2007 Jan 1;13(1):307-15. doi: 10.1158/1078-0432.CCR-06-1430. Epub 2006 Dec 14.
3
alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.甲胎蛋白和白细胞介素-18基因修饰的树突状细胞在体外能有效刺激肝癌患者产生特异性1型CD4和CD8介导的T细胞应答。
Hum Immunol. 2007 May;68(5):334-41. doi: 10.1016/j.humimm.2007.01.008. Epub 2007 Feb 21.
4
A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy.一种用于癌症免疫治疗中靶向共刺激的新型抗体-4-1BBL融合蛋白。
J Immunother. 2008 Oct;31(8):714-22. doi: 10.1097/CJI.0b013e31818353e9.
5
[Investigation on specific killing acute leukemia cell reaction of the cytotoxic T lymphocyte induced by dendritic cell pulsed with frozen-thawed antigen].[冻融抗原负载树突状细胞诱导的细胞毒性T淋巴细胞特异性杀伤急性白血病细胞反应的研究]
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2004 Dec;21(6):974-8.
6
[In vitro anti-tumor effect of CTL induced by HSP70-Id complex-modified dendritic cells].[热休克蛋白70-Id复合物修饰的树突状细胞诱导的细胞毒性T淋巴细胞的体外抗肿瘤作用]
Zhonghua Zhong Liu Za Zhi. 2006 Jul;28(7):481-5.
7
4-1BB (CD137) ligand enhanced anti-tumor immune response against mouse forestomach carcinoma in vivo.4-1BB(CD137)配体增强了体内针对小鼠前胃癌的抗肿瘤免疫反应。
Cell Mol Immunol. 2008 Oct;5(5):379-84. doi: 10.1038/cmi.2008.47.
8
[Changes in immune function of dendritic cells infected by recombinant adenovirus containing Her2/neu gene of extracellular and transmembrane domain proteins].[含细胞外和跨膜结构域蛋白Her2/neu基因的重组腺病毒感染的树突状细胞免疫功能变化]
Nan Fang Yi Ke Da Xue Xue Bao. 2006 Aug;26(8):1184-7.
9
Anti-prostate cancer effects of CTL cell induction in vitro by recombinant adenovirus mediated PSMA/4-1BBL dendritic cells: an immunotherapy study.重组腺病毒介导的PSMA/4-1BBL树突状细胞体外诱导CTL细胞的抗前列腺癌作用:一项免疫治疗研究。
Genet Mol Res. 2015 Jun 29;14(2):7208-17. doi: 10.4238/2015.June.29.14.
10
The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.全身性给予Ig-4-1BB配体并联合白细胞介素-12基因转移可根除肝结肠癌。
Gene Ther. 2005 Oct;12(20):1526-33. doi: 10.1038/sj.gt.3302556.

引用本文的文献

1
Ex vivo nicotine stimulation augments the efficacy of human peripheral blood mononuclear cell-derived dendritic cell vaccination via activating Akt-S6 pathway.体外尼古丁刺激通过激活Akt-S6信号通路增强人外周血单个核细胞来源的树突状细胞疫苗的疗效。
Anal Cell Pathol (Amst). 2015;2015:741487. doi: 10.1155/2015/741487. Epub 2015 Aug 13.
2
Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.用抗CD137抗体疗法增强癌症免疫疗法。
Clin Cancer Res. 2015 Jul 15;21(14):3113-20. doi: 10.1158/1078-0432.CCR-15-0263. Epub 2015 Apr 23.
3
Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata.
毛囊周围肥大细胞与CD8 + T细胞之间的异常相互作用可能导致斑秃的发病机制。
PLoS One. 2014 May 15;9(5):e94260. doi: 10.1371/journal.pone.0094260. eCollection 2014.
4
Analysis of CD137L and IL-17 expression in tumor tissue as prognostic indicators for gliblastoma.分析肿瘤组织中 CD137L 和 IL-17 的表达作为胶质母细胞瘤的预后指标。
Int J Biol Sci. 2013;9(2):134-41. doi: 10.7150/ijbs.4891. Epub 2013 Jan 16.
5
Nicotine up-regulated 4-1BBL expression by activating Mek-PI3K pathway augments the efficacy of bone marrow-derived dendritic cell vaccination.尼古丁通过激活 Mek-PI3K 通路上调 4-1BBL 的表达,增强了骨髓来源树突状细胞疫苗的疗效。
J Clin Immunol. 2013 Jan;33(1):246-54. doi: 10.1007/s10875-012-9761-5. Epub 2012 Aug 17.